Pregnancy outcomes in women with type 1 diabetes using insulin degludec.

Content Provider	Europe PMC
Author	Ringholm, Lene Do, Nicoline Callesen Damm, Peter Mathiesen, Elisabeth Reinhardt
Abstract	AimsTo evaluate pregnancy outcomes in a real-world setting of pregnant women with type 1 diabetes using the ultra-long-acting insulin analog degludec compared to other long-acting insulin analogs throughout pregnancy.MethodsThis was a secondary analysis of a prospective cohort study. The prospective cohort included consecutive, singleton pregnant women with type 1 diabetes receiving long-acting insulin analogs both before and during pregnancy: 67 women using degludec compared to 95 women using other long-acting insulin analogs in a routine care setting.ResultsWomen using degludec had similar clinical characteristics as women using other long-acting insulin analogs including HbA1c at 9 gestational weeks [6.5 (6.2–6.9) % (48 (44–52) mmol/mol) versus 6.5 (6.0–7.0) % (47 (42–53) mmol/mol), p = 0.52] and at 35 gestational weeks [6.0 (5.6–6.5) % (42 (38–47) mmol/mol) versus 6.1 (5.6–6.5) % (43 (38–48) mmol/mol), p = 0.68]. Pregnancy outcomes were similar regarding preeclampsia [10% (7/67) versus 8% (8/95), p = 0.66] and preterm delivery before 37 gestational weeks [16% (11/67) versus 23% (22/95), p = 0.29]. There were no perinatal deaths, and neonatal outcomes as large for gestational age infants [37% (25/67) versus 39% (37/95), p = 0.83], small for gestational age infants [4% (3/67) versus 5% (5/95), p = 1.0] and neonatal hypoglycemia [32% (21/65) versus 41% (34/83), p = 0.28] were similar between women using degludec and other long-acting insulin analogs.ConclusionsThe use of degludec during pregnancy resulted in similar pregnancy outcomes as use of other long-acting insulin analogs in women with type 1 diabetes in a real-world setting. This suggests that degludec initiated before pregnancy can be continued throughout gestation.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8853215&blobtype=pdf
ISSN	09405429
Journal	Acta Diabetologica [Acta Diabetol]
Volume Number	59
DOI	10.1007/s00592-021-01845-0
PubMed Central reference number	PMC8853215
Issue Number	5
PubMed reference number	35147781
e-ISSN	14325233
Language	English
Publisher	Springer Milan
Publisher Date	2022-02-11
Publisher Place	Milan
Access Restriction	Open
Rights License	This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. © Springer-Verlag Italia S.r.l., part of Springer Nature 2022
Subject Keyword	Pregnancy Type 1 diabetes Degludec Long-acting insulin analog Pregnancy outcomes Neonatal outcomes
Content Type	Text
Resource Type	Article
Subject	Endocrinology, Diabetes and Metabolism Internal Medicine Endocrinology